Get started
MERCK & CO.MM

MERCK & CO.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

4MRKX trade ideas

MRK Long, 60M Demand ZoneThe Highlighted Area had been traded many times. Buy orders and Sell orders had been filled by each other. Once demand zone got confirmed, This area will be treated as GAP. Earning will not affect this trade. Entry: 74.5 (Below 75) Stop: 72.8; Below Demand zone Target: 82; risk/reward=1:4 This is a trading school homework. I need few months to practice trading plan. If you like it, thank you for your support. Please use SIM/Demo account to try it, until my trading plans get high winning rate.
NLong
by PlanTradePlanMM
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again. But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in. Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NLong
by ChristopherCarrollSmith
3